An observational study in Alzheimer Disease, Biomarkers / Blood and Biomarker in Early Diagnosis, sponsored by Imperial College London. Not yet recruiting. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Imperial College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Alzheimer Disease by Imperial College London — 6 open to participants now, 7 under way, 1 of them phase 3. Alzheimer Disease · Imperial College London.
Among the 11 studies in Alzheimer Disease by Imperial College London, this one is the only one that started in 2026, is one of 3 observational ones, and was the 11th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →6 of the 11 studies in Alzheimer Disease by Imperial College London are open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 65+ · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18–90 · Healthy volunteers
Imperial College London
Ages 50+
Imperial College London
Ages 50+
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 104 across the 8 interventional studies, 700 across the 3 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
2 of the studies in Alzheimer Disease by Imperial College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07401849Imperial College LondonBlood Biomarkers for Early and Accurate Diagnosis of Alzheimer's Disease in Primary Care | 2026-11 |
| NCT07191821Imperial College LondonTSPO Modulation in AD | 2027-03-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Alzheimer Disease by Imperial College London, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Alzheimer's disease is a degenerative condition affecting the brain and is the most common form of dementia in older adults. Dementia is currently a major healthcare issue in the UK, affecting approximately a million people. The progression of the disease varies between individuals and the early stages may be characterised by only minimal changes in memory and thinking. These changes could remain undetected as the symptoms may be mistakenly regarded as normal age-related forgetfulness. However, dementia is not part of the normal ageing process.
The underlying biological disease process of Alzheimer's is now known to start at least 20 years prior to patients showing any symptoms. A protein called amyloid starts to deposit in the brain and forms clumps referred to as 'plaques'. Another protein called tau collects inside brain cells and forms structures called 'tangles'. These biological changes can disrupt the normal functioning of brain cells and ultimately destroy them, leading to a reduction in brain volume and ability.
The aim of the BEAD-PC study is to assess whether a specific blood test in primary care can help diagnose Alzheimer's disease at an early stage.
Eligible patients from 124 GP surgeries England.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Presence of Alzheimer-specific blood biomarkers
Amyloid and Tau protein biomarkers identified in blood sample
Time frame: Day 1 (study entry)
Presence of Alzheimer-specific Cerebrospinal Fluid (CSF) biomarkers
Amyloid and Tau protein biomarkers found in CSF
Time frame: Follow-up visit (around 6 months after study entry)
Montreal Cognitive Assessment (MoCA) score
Pen-and-paper cognitive test commonly used to identify Mild Cognitive Impairment (MCI) in older adults.
Time frame: Day 1 (study entry)
CANTAB score
Online, self-completed battery of cognitive tests validated for detecting signs of AD-related cognitive decline.
Time frame: Day 1 (study entry)
No study locations are listed for this record.
Start is estimated for Feb 2026; primary completion for Nov 2026, 9 months later.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 9 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.